Provided by Tiger Fintech (Singapore) Pte. Ltd.

I-MAB

3.72
+0.10002.76%
Pre-market: 3.58-0.1397-3.76%08:18 EDT
Volume:1.19M
Turnover:4.47M
Market Cap:427.78M
PE:-8.20
High:3.86
Open:3.62
Low:3.52
Close:3.62
52wk High:5.90
52wk Low:0.5950
Shares:114.99M
Float Shares:48.23M
Volume Ratio:0.50
T/O Rate:2.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4537
EPS(LYR):-0.2738
ROE:-17.08%
ROA:-10.36%
PB:2.17
PE(LYR):-13.59

Loading ...

BUZZ-I-Mab tumbles on China drug report, analyst calls selloff overreaction

Reuters
·
Sep 11

BTIG says buy I-Mab amid ‘misperceived’ China risk

TIPRANKS
·
Sep 11

I-Mab Price Target Maintained With a $7.00/Share by BTIG

Dow Jones
·
Sep 11

BTIG Initiates I-MAB at Buy With $7 Price Target

MT Newswires Live
·
Sep 09

I-Mab Price Target Maintained With a $6.00/Share by Needham

Dow Jones
·
Sep 08

BRIEF-I-Mab Announces Acceleration Of Givastomig Investment And Leadership Appointments

Reuters
·
Sep 08

BRIEF-I-Mab Wei Fu, I-Mab’S Chairman Of Board, Appointed As Executive Chairman

Reuters
·
Sep 08

I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

THOMSON REUTERS
·
Sep 08

I-Mab: Plans Global Phase 2 Study for Givastomig in Q1 2026

THOMSON REUTERS
·
Sep 08

I-Mab: Wei Fu, I-Mab’s Chairman of Board, Appointed as Executive Chairman

THOMSON REUTERS
·
Sep 08

I-Mab Announces Global Phase 2 Trial Initiation for Givastomig in Metastatic Gastric Cancers, Set for Q1 2026

Reuters
·
Sep 08

Stock Track | I-Mab Shares Plummet 5.30% Following Board and Advisory Appointments

Stock Track
·
Aug 26

Stock Track | I-Mab Soars 5.70% Pre-market on Board Appointments and R&D Committee Formation

Stock Track
·
Aug 25

Stock Track | I-MAB Surges 5.70% Pre-Market on Board Appointments and R&D Committee Formation

Stock Track
·
Aug 25

Press Release: I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

Dow Jones
·
Aug 25

Stock Track | I-MAB (IMAB) Soars 6.19% on Positive Analyst Ratings and Upcoming Investor Conferences

Stock Track
·
Aug 21

I-Mab to Participate in September Investor Conferences

GlobeNewswire
·
Aug 21

I-Mab Is Maintained at Buy by Needham

Dow Jones
·
Aug 21

I-MAB Q2 EPADS $(0.07) Up From $(0.11) YoY , Cash And Cash Equivalents, And Short-term Investments Of $165.6M Expected To Provide Cash Runway Into Q4 Of 2028

Benzinga
·
Aug 20

I-Mab Reports Q2 2025 Loss of $5.5M, EPS Declines to $(0.03) from $0.13 in Prior Year

Reuters
·
Aug 20